Blurbs

H.C. Wainwright Remains a Buy on Werewolf Therapeutics (HOWL)

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Werewolf Therapeutics (HOWLResearch Report) today and set a price target of $20.00. The company’s shares closed yesterday at $2.29.

According to TipRanks, Y. Maldonado is ranked #6756 out of 7983 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Werewolf Therapeutics with a $20.00 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Werewolf Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.15 million and a GAAP net loss of $14.59 million. In comparison, last year the company had a GAAP net loss of $10.92 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.

Read More on HOWL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More